These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28192480)

  • 1. mTOR activity in AIDS-related diffuse large B-cell lymphoma.
    Browne SH; Diaz-Perez JA; Preziosi M; King CC; Jones GA; Jain S; Sun X; Reid EG; VandenBerg S; Wang HY
    PLoS One; 2017; 12(2):e0170771. PubMed ID: 28192480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
    Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
    Kim HS; Kim GY; Lim SJ; Kim YW
    Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
    Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.
    Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S
    PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].
    Li JF; Li GD; Gu L; Liu WP; Li FY; Liao DY; Ma ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):649-53. PubMed ID: 19176054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
    Márk Á; Hajdu M; Váradi Z; Sticz TB; Nagy N; Csomor J; Berczi L; Varga V; Csóka M; Kopper L; Sebestyén A
    BMC Cancer; 2013 May; 13():250. PubMed ID: 23693095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray.
    Xiao L; Wang YC; Li WS; Du Y
    J Exp Clin Cancer Res; 2009 Dec; 28(1):152. PubMed ID: 20003385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
    Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
    J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
    Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
    Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
    Liontos M; Trigka EA; Korkolopoulou P; Tzannis K; Lainakis G; Koutsoukos K; Kostouros E; Lykka M; Papandreou CN; Karavasilis V; Christodoulou C; Papatsoris A; Skolarikos A; Varkarakis I; Adamakis I; Alamanis C; Stravodimos K; Mitropoulos D; Deliveliotis C; Constantinidis CA; Saetta A; Patsouris E; Dimopoulos MΑ; Bamias A
    World J Urol; 2017 Mar; 35(3):411-419. PubMed ID: 27395374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.
    Sebestyén A; Sticz TB; Márk A; Hajdu M; Timár B; Nemes K; Nagy N; Váradi Z; Kopper L
    Mod Pathol; 2012 Dec; 25(12):1623-8. PubMed ID: 22899290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma.
    Li N; Zhong M; Song M
    Int J Clin Exp Pathol; 2012; 5(7):660-7. PubMed ID: 22977662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
    Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.